| Target Price | $10.20 |
| Price | $2.58 |
| Potential |
295.35%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target MediciNova, Inc. 2027 .
The average MediciNova, Inc. target price is $10.20.
This is
295.35%
register free of charge
$11.55
347.67%
register free of charge
$6.06
134.88%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend MediciNova, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the MediciNova, Inc. stock has an average upside potential 2027 of
295.35%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.41 | 0.53 |
| 28.12% | ||
| EBITDA Margin | -3,234.15% | -2,873.79% |
| 11.14% | ||
| Net Margin | -2,926.83% | -2,484.89% |
| 15.10% |
5 Analysts have issued a sales forecast MediciNova, Inc. 2026 . The average MediciNova, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an MediciNova, Inc. EBITDA forecast 2026. The average MediciNova, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 MediciNova, Inc. Analysts have issued a net profit forecast 2026. The average MediciNova, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.24 | -0.27 |
| 4.35% | 12.50% | |
| P/E | negative | |
| EV/Sales | 193.36 |
5 Analysts have issued a MediciNova, Inc. forecast for earnings per share. The average MediciNova, Inc. EPS is
This results in the following potential growth metrics and future valuations:
MediciNova, Inc....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Roth Capital |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | May 04 2026 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Mar 23 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 16 2026 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jan 30 2026 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Dec 18 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Dec 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Roth Capital:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
May 04 2026 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Mar 23 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 16 2026 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jan 30 2026 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Dec 18 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Dec 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


